Table 2 The efficacy of Cas9-mediated modifications in goat fibroblasts and tested individuals.
From: Generation of gene-modified goats targeting MSTN and FGF5 via zygote injection of CRISPR/Cas9 system
Target gene | Fibroblasts | Tested individuals |
|---|---|---|
MSTN | 15/26 (57.7%) | 15/98 (15.3%) |
FGF5 | 11/18 (61.1%) | 21/98 (21.4%) |
FGF5&MSTN | − | 10/98 (10.2%) |
